The Down syndrome-associated arthritis Cohort in the new Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes.

There was little difference between patients with DA and JIA at baseline and similar therapy was implemented for those in the nCARRA, however, at the last visit those with DA had more disease burden. Additionally, there were more DMARD adverse events and biologic ineffectiveness for those with DA. More research is needed to determine differences in pathophysiology and optimal therapeutic approaches.